# Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

> **NCT06585150** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 150 (actual)

## Conditions studied

- RSV Infection

## Interventions

- **DRUG:** Obeldesivir
- **DRUG:** Obeldesivir Placebo

## Key facts

- **NCT ID:** NCT06585150
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-14
- **Primary completion:** 2025-05-08
- **Final completion:** 2025-06-09
- **Target enrollment:** 150 (ACTUAL)
- **Why stopped:** Study was terminated by Sponsor; the decision was not due to any safety findings.
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06585150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06585150, "Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06585150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*